Australian researchers have made a significant breakthrough in diagnosing endometriosis with the development of a blood test that could detect the condition in its early stages. The test, called PromarkerEndo, was developed by Perth-based medical technology company Proteomics International and the findings were published in the journal Human Reproduction.
“This is an exciting advance in the diagnosis of this debilitating disease,” said Professor Peter Rogers, research director at the Royal Women’s Hospital and professor of women’s health research at the University of Melbourne. “Currently, it takes an average of seven years for a woman to receive a diagnosis. During that time, she endures significant symptoms, her fertility diminishes, and the disease progresses.”
Faster, Less Invasive Diagnosis
The test identifies 10 protein biomarkers—or “fingerprints”—in the blood that are associated with early-stage endometriosis. This non-invasive method is a stark contrast to the current diagnostic tools, which often rely on costly and invasive procedures such as laparoscopies, MRIs, and biopsies.
Proteomics International’s managing director, Dr. Richard Lipscombe, highlighted the potential impact of the test. “PromarkerEndo could significantly reduce both the cost and the time it takes to diagnose endometriosis,” he said. “This would spare women years of uncertainty and suffering.”
A Common but Underdiagnosed Condition
Endometriosis affects one in nine women and girls in Australia. It occurs when tissue similar to the lining of the uterus grows in other parts of the body, causing symptoms such as severe pelvic pain, painful periods, and infertility. According to Endometriosis Australia, the disease costs the country $9.7 billion annually, with 70% of affected women needing time off work to manage their symptoms.
Collaborative Research and Promising Results
The blood test was developed through a study of 805 participants, with researchers from Proteomics International collaborating with experts from the Royal Women’s Hospital and the University of Melbourne. The test demonstrated excellent results in distinguishing between healthy individuals, symptomatic women, and those with early-stage endometriosis.
“Detecting endometriosis early opens the door to more treatment options and better outcomes,” said Rogers. “It may improve patients’ responses to laser ablation or existing medical therapies.”
Hope for the Future
While there is no cure for endometriosis, early diagnosis and effective management are crucial. Researchers are now working to enhance the reliability and clinical readiness of PromarkerEndo, bringing hope to millions of women.
“This test could transform how we diagnose and manage endometriosis, making life easier for countless women and girls,” said Lipscombe.
As the medical community continues to focus on innovation, the development of PromarkerEndo is a promising step toward alleviating the significant physical, emotional, and financial burden of endometriosis.
Related topics:
Gameto’s Breakthrough in Egg Maturation Could Revolutionize IVF
New Data Reveals High Endometriosis Diagnoses in Oxfordshire, Highlighting Need for More Support
